CR11763A - Conjugados de factor ix con vidas medias extendidas - Google Patents

Conjugados de factor ix con vidas medias extendidas

Info

Publication number
CR11763A
CR11763A CR11763A CR11763A CR11763A CR 11763 A CR11763 A CR 11763A CR 11763 A CR11763 A CR 11763A CR 11763 A CR11763 A CR 11763A CR 11763 A CR11763 A CR 11763A
Authority
CR
Costa Rica
Prior art keywords
factor
conjugates
lives
extended medium
extended
Prior art date
Application number
CR11763A
Other languages
English (en)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of CR11763A publication Critical patent/CR11763A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a conjugados del Factor IX que han sido modificados para incluir una porción del polímero biocompatible. Los conjugados del Factor IX están sustancialmente libres de contaminación por el Factor IXa.
CR11763A 2008-04-24 2010-10-27 Conjugados de factor ix con vidas medias extendidas CR11763A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4754408P 2008-04-24 2008-04-24

Publications (1)

Publication Number Publication Date
CR11763A true CR11763A (es) 2011-04-26

Family

ID=41171051

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11763A CR11763A (es) 2008-04-24 2010-10-27 Conjugados de factor ix con vidas medias extendidas

Country Status (23)

Country Link
US (1) US20110183906A1 (es)
EP (1) EP2280734B1 (es)
JP (1) JP2011519833A (es)
KR (1) KR20110016440A (es)
CN (1) CN102046205A (es)
AU (1) AU2009239641B2 (es)
BR (1) BRPI0911350A2 (es)
CA (1) CA2722169A1 (es)
CO (1) CO6300965A2 (es)
CR (1) CR11763A (es)
DK (1) DK2280734T3 (es)
EC (1) ECSP10010632A (es)
ES (1) ES2466340T3 (es)
HK (1) HK1151986A1 (es)
IL (1) IL208908A0 (es)
MX (1) MX2010011672A (es)
MY (1) MY158228A (es)
NI (1) NI201000177A (es)
NZ (1) NZ588854A (es)
RU (1) RU2496521C2 (es)
UA (1) UA101497C2 (es)
WO (1) WO2009130602A2 (es)
ZA (1) ZA201007559B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
ES2590679T3 (es) 2009-07-27 2016-11-23 Lipoxen Technologies Limited Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
KR101832937B1 (ko) 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
AU2010284977A1 (en) * 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EA037095B1 (ru) 2010-07-09 2021-02-05 Биовератив Терапьютикс Инк. Способ лечения гемофилии в и эпизодов кровотечения
EA032056B1 (ru) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты)
CA2836478A1 (en) * 2011-05-27 2012-12-06 Baxter International Inc. Therapeutic protein conjugated to water-soluble polymers via reduced cysteine sulfhydryl group
IL235129B (en) * 2012-04-16 2022-06-01 Cantab Biopharmaceuticals Patents Ltd Therapeutic compounds for subcutaneous administration
RU2015101333A (ru) * 2012-06-19 2016-08-10 Политерикс Лимитед Новый способ получения конъюгатов антител и новые конъюгаты антител
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
TWI683666B (zh) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
GB2564389A (en) 2017-07-04 2019-01-16 Green Running Ltd A system and method for utility management

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
AU783512B2 (en) * 2000-02-11 2005-11-03 Bayer Healthcare Llc Factor VII or VIIa-like molecules
JP4490369B2 (ja) * 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション マレアミド酸ポリマー誘導体及びこれらの生物学的複合体
EP1578842B1 (en) * 2002-12-31 2009-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US7910661B2 (en) * 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
DE602004025157D1 (de) 2003-09-23 2010-03-04 Univ North Carolina Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ｉｘ因子調製物およびその精製方法
ES2344413T3 (es) 2003-10-14 2010-08-26 Baxter International Inc. Polipeptido vkorc1 de reciclaje de la vitamina k-epoxido, una diana terapeutica de la cumarina y sus derivados.
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101146160B1 (ko) * 2004-06-30 2012-07-16 넥타르 테라퓨틱스 중합체­인자 ｉｘ 부분의 접합체
CA2590284A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
EP2295547B1 (en) 2005-02-28 2017-09-20 Baxalta GmbH Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependant protein expression
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
KR20080108147A (ko) * 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
MX2008014685A (es) * 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病ｂ治療剤及びその製造方法

Also Published As

Publication number Publication date
CA2722169A1 (en) 2009-10-29
ECSP10010632A (es) 2011-02-28
AU2009239641B2 (en) 2013-11-07
WO2009130602A9 (en) 2010-04-22
ZA201007559B (en) 2012-01-25
WO2009130602A3 (en) 2010-02-11
US20110183906A1 (en) 2011-07-28
MX2010011672A (es) 2011-03-02
DK2280734T3 (da) 2014-05-26
CO6300965A2 (es) 2011-07-21
EP2280734B1 (en) 2014-02-26
RU2496521C2 (ru) 2013-10-27
MY158228A (en) 2016-09-15
JP2011519833A (ja) 2011-07-14
WO2009130602A2 (en) 2009-10-29
CN102046205A (zh) 2011-05-04
AU2009239641A1 (en) 2009-10-29
NI201000177A (es) 2011-08-29
ES2466340T3 (es) 2014-06-10
KR20110016440A (ko) 2011-02-17
EP2280734A2 (en) 2011-02-09
IL208908A0 (en) 2011-01-31
RU2010147813A (ru) 2012-05-27
BRPI0911350A2 (pt) 2017-12-05
NZ588854A (en) 2011-12-22
HK1151986A1 (en) 2012-02-17
UA101497C2 (ru) 2013-04-10

Similar Documents

Publication Publication Date Title
CR11763A (es) Conjugados de factor ix con vidas medias extendidas
CU20110109A7 (es) Nueva composición a base de ácido gamma-hidroxibutírico
CR20110002S (es) Barra de chocolate
CO6400230A2 (es) Conjugados de insulina cristalina
SMT201400030B (it) Profarmaci del dolutegravir
CR20130337A (es) Amida aminoindanes con una alta actividad fungicida y sus composiciones fito sanitarias
CR11361A (es) Moleculas y metodos para modular el componente de complemento
AR058057A1 (es) Composicion de estabilidad aumentada y un procedimiento para preparar una composicion de este tipo
HN2008001466A (es) Forma galenica divisible que permite una liberacion modificada del principio activo
DOP2011000393A (es) Derivados de pirazinooxazepina
GB2476926B (en) Tuneable quantum light source
BR112012026157A2 (pt) processo para preparar ditiina-tetracarboximidas.
UY34408A (es) Nuevos moduladores de trpv3
AR078548A1 (es) Composicion tonalizadora
FR2945103B3 (fr) Plaque lumineuse a del fine
HN2010002052S1 (es) Blanco para una llave
FR2944579B1 (fr) Support de source lumineuse du type diode electroluminescente.
UY33560A (es) Compuestos heterociclicos
ES2404379R1 (es) Elemento de soporte para un aparato doméstico, disposición con un elemento de soporte de tal tipo, y aparato doméstico con una disposición correspondiente
ES1070779Y (es) Fuente ornamental con proyector luminoso integrado
BRPI0600656A (pt) seringa com travamento
CL2008003510S1 (es) Placa para tensionar cordel.
CL2008000275S1 (es) Perfil.
CL2008000267S1 (es) Perfil.
CL2008000265S1 (es) Perfil.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)